Arbutus Biopharma | Investor Presentation Deck | 25 slides

Arbutus Biopharma · 2023-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

25
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide outlines the core therapeutic strategy of Arbutus Biopharma.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
04
The slide uses a column-based layout to present key value propositions.summarize
Open slide detailBeat · SolutionLoop · Golden Circle
05
plan_implementation
Open slide detailBeat · SolutionLoop · Golden Circle
06
The slide uses a four-column layout to structure the disease overview.establish_context
Open slide detailBeat · Problem
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
08
The slide uses a process-oriented flow diagram to explain the mechanism of action for a combination therapy.present_solution
Open slide detailLoop · Cost Of Inaction
09
transition
10
The slide highlights the mechanism of action and key therapeutic benefits of the drug candidate.present_solution
Open slide detailBeat · Product
11
The slide outlines the study design for cohorts E through K in Part 3 of the trial.analyze_data
Open slide detailBeat · Product
12
Data shows consistent efficacy across different patient subgroups.analyze_data
Open slide detailBeat · Product
13
The slide displays longitudinal clinical trial data for a drug candidate (Imdusiran) across various dosing regimens (Cohorts E, F, I, J, G, K).show_traction
Open slide detailBeat · Product
14
Clinical trial data showing individual patient responses over time, including two cases of NA retreatment.show_traction
Open slide detailBeat · Product
15
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.show_traction
Open slide detailBeat · Product
16
The slide uses a bulleted list to present key safety outcomes, including lack of serious adverse events and stability of laboratory markers.summarize
17
summarize
18
The slide uses a timeline-based process diagram to illustrate the clinical trial randomization and treatment arms.show_traction
19
Shows two parallel trial arms with timelines and patient counts.plan_implementation
20
The slide details the financial terms of the deal and the scope of the partnership.other
21
transition
22
Includes two distinct charts: a bar chart showing IFN-y fold increase and a line chart showing tumor volume reduction over time.show_traction
23
The slide uses a three-column layout to explain the scientific basis and product advantages.present_solution
24
The slide includes a financial summary at the top and a list of clinical trial milestones with completion checkmarks.plan_implementation
Open slide detailBeat · The Ask
25
state_next_steps
Open slide detailBeat · The Ask